Lv1
16 积分 2023-05-03 加入
Adjuvant Endocrine Therapy
2个月前
已完结
HER2 as a Predictive Factor for Successful Neoadjuvant Anthracycline Chemotherapy of Locally Advanced and Early Breast Cancer
4个月前
已完结
HER2-Positive Urothelial Carcinoma: Current Evidence on Targeted Agents and Immunotherapy-Based Combinations
5个月前
已完结
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial
7个月前
已完结
The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial
7个月前
已关闭
Comprehensive analysis of adverse event profile changes with pertuzumab addition to trastuzumab‐based breast cancer therapy: Disproportionality analysis using VigiBase
7个月前
已完结
CDK4/6 Inhibitor Resistance in ER+ Breast Cancer
7个月前
已完结
Next-generation sequencing for PTEN testing in HR+/HER2˗ metastatic breast cancer
7个月前
已完结
Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer
8个月前
已完结
New Guidelines for Statistical Reporting
8个月前
已完结
皖公网安备34019202002308
